Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

This study has been completed.
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00190866
First received: September 12, 2005
Last updated: November 5, 2007
Last verified: November 2007